AU2007211840B2 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors - Google Patents

Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Download PDF

Info

Publication number
AU2007211840B2
AU2007211840B2 AU2007211840A AU2007211840A AU2007211840B2 AU 2007211840 B2 AU2007211840 B2 AU 2007211840B2 AU 2007211840 A AU2007211840 A AU 2007211840A AU 2007211840 A AU2007211840 A AU 2007211840A AU 2007211840 B2 AU2007211840 B2 AU 2007211840B2
Authority
AU
Australia
Prior art keywords
optionally substituted
methoxy
hydroxy
trimethoxybenzoyl
ome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007211840A
Other languages
English (en)
Other versions
AU2007211840A1 (en
Inventor
Jason Hugh Chaplin
Bernard Luke Flynn
Gurmit Singh Gill
Damian Wojciech Grobelny
Gabriel Kremmidiotis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Publication of AU2007211840A1 publication Critical patent/AU2007211840A1/en
Application granted granted Critical
Publication of AU2007211840B2 publication Critical patent/AU2007211840B2/en
Priority to AU2012203083A priority Critical patent/AU2012203083A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2007211840A 2006-02-03 2007-02-02 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Ceased AU2007211840B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012203083A AU2012203083A1 (en) 2006-02-03 2012-05-25 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76533706P 2006-02-03 2006-02-03
US60/765,337 2006-02-03
PCT/AU2007/000101 WO2007087684A1 (en) 2006-02-03 2007-02-02 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012203083A Division AU2012203083A1 (en) 2006-02-03 2012-05-25 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Publications (2)

Publication Number Publication Date
AU2007211840A1 AU2007211840A1 (en) 2007-08-09
AU2007211840B2 true AU2007211840B2 (en) 2012-03-01

Family

ID=38327089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007211840A Ceased AU2007211840B2 (en) 2006-02-03 2007-02-02 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Country Status (11)

Country Link
US (5) US8198466B2 (https=)
EP (2) EP2460793A1 (https=)
JP (1) JP5315060B2 (https=)
AT (1) ATE555091T1 (https=)
AU (1) AU2007211840B2 (https=)
CA (1) CA2640678C (https=)
DK (1) DK1984333T3 (https=)
ES (1) ES2386299T3 (https=)
NZ (1) NZ570014A (https=)
PT (1) PT1984333E (https=)
WO (1) WO2007087684A1 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
EA011211B1 (ru) 2003-11-20 2009-02-27 Янссен Фармацевтика Н. В. 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
MXPA06014933A (es) 2004-06-30 2007-02-28 Janssen Pharmaceutica Nv Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1.
SG154433A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Phthalazine derivatives as parp inhibitors
MXPA06014541A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa.
AU2007211840B2 (en) 2006-02-03 2012-03-01 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
CA2716726C (en) 2008-03-27 2017-01-24 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
JP5464609B2 (ja) 2008-03-27 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
CN102596197A (zh) * 2009-08-27 2012-07-18 生物学特性有限公司 用于治疗增生性疾病的联合疗法
JP2013502440A (ja) * 2009-08-27 2013-01-24 バイオノミックス リミテッド 黄斑変性の治療
AU2009240878B2 (en) * 2009-11-27 2016-05-26 Bionomics Limited Combination Therapy for Treating Proliferative Diseases
WO2011063469A1 (en) * 2009-11-27 2011-06-03 Bionomics Limited Tubulin biomarker assay
US20110130367A1 (en) * 2009-11-27 2011-06-02 Bionomics Limited Combination Therapy for Treating Proliferative Diseases
US20130131018A1 (en) 2010-06-04 2013-05-23 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2012006686A1 (en) 2010-07-16 2012-01-19 Bionomics Limited Chemical processes for the manufacture of substituted benzofurans
FR2962731B1 (fr) * 2010-07-19 2012-08-17 Sanofi Aventis Procede de preparation de derives d'amino-benzoyl-benzofurane
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
CN103221048A (zh) 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法
EP2648509B1 (en) * 2010-12-09 2015-04-29 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
US9039732B2 (en) 2011-07-11 2015-05-26 Covidien Lp Surgical forceps
WO2013048177A2 (ko) * 2011-09-28 2013-04-04 세종대학교산학협력단 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
CN103058988B (zh) * 2012-12-31 2015-09-02 中国人民大学 苯并噻吩及其衍生物及其制备方法与应用
WO2014175623A1 (ko) * 2013-04-26 2014-10-30 한국생명공학연구원 신규 튜불린 중합 저해제 및 그 합성방법
KR101584731B1 (ko) 2013-04-26 2016-01-12 한국생명공학연구원 신규 튜불린 중합 저해제 및 그 합성방법
NZ724796A (en) * 2014-04-04 2019-04-26 Bionomics Ltd Method for treating chronic lymphocytic leukemia
US20170119727A1 (en) * 2014-05-30 2017-05-04 Bionomics Limited A therapeutic protocol for treating ovarian cancer
AU2015283811A1 (en) * 2014-07-02 2017-02-09 Bionomics Limited Predictive biomarkers
US10159659B2 (en) * 2014-07-02 2018-12-25 Bionomics Limited Predicting response to cancer therapy
CN104860908B (zh) * 2015-04-28 2017-03-22 广东颐正达医药科技有限公司 一种合成bnc105的方法
AU2016275574B2 (en) * 2015-06-11 2019-07-11 Bionomics Limited Pharmaceutical combination and uses thereof
SMT202300018T1 (it) 2015-12-09 2023-03-17 Univ Illinois Downregolatori del recettore degli estrogeni a base di benzotiofene
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3858835A1 (en) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
CN107586284B (zh) * 2016-07-06 2021-03-26 中国药科大学 一种2-芳基苯并呋喃类衍生物在制备痛风药物中的用途
KR20190053909A (ko) * 2016-09-16 2019-05-20 바이오노믹스 리미티드 항체와 체크포인트 면역 억제제의 병용 요법
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
FI3645001T3 (fi) 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
BR112022011827A2 (pt) 2019-12-20 2022-08-30 C4 Therapeutics Inc Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção
KR102894542B1 (ko) * 2020-01-30 2025-12-03 (주)에임드바이오 벤조셀레노펜계 화합물, 이를 포함하는 약학적 조성물 및 항체-약물 결합체
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
EP4192458A4 (en) 2020-08-05 2024-09-04 C4 Therapeutics, Inc. COMPOUNDS FOR TARGETED DEGRADATION OF RET
WO2022261250A1 (en) 2021-06-08 2022-12-15 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
US12575874B2 (en) 2021-09-10 2026-03-17 Covidien Lp Cutting blade for vessel sealer with knife return
JP2025525917A (ja) 2022-08-03 2025-08-07 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔタンパク質を調節するための化合物
CN120569388A (zh) 2022-11-04 2025-08-29 百时美施贵宝公司 Ret-ldd蛋白降解剂
CN120530116A (zh) 2022-11-04 2025-08-22 百时美施贵宝公司 Ret-ldd蛋白抑制剂
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006212726A1 (en) * 2005-02-14 2006-08-17 Bionomics Limited Novel tubulin polymerisation inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135173A1 (en) 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
EP0641204B1 (en) 1992-05-20 2000-08-16 Merck & Co. Inc. 17-ethers and thioethers of 4-aza-steroids
EP0915090A1 (en) 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
DE69427283T2 (de) * 1993-11-17 2001-09-13 Kyowa Hakko Kogyo Co., Ltd. Propenon-derivate
US5728724A (en) * 1995-08-17 1998-03-17 Eli Lilly And Company Benzothiophene compounds
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
WO2004099139A1 (en) * 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
JP4187441B2 (ja) 1999-09-17 2008-11-26 ベイラー・ユニバーシテイ インドール含有およびコンブレタスタチン関連の抗有糸分裂および抗チューブリン重合薬剤
DE60030303T2 (de) 1999-10-18 2007-10-11 The University Of Connecticut, Farmington Cannabimimetische indolderivate
WO2001051456A2 (en) 2000-01-13 2001-07-19 Tularik Inc. Antibacterial agents
WO2001068654A2 (en) 2000-03-10 2001-09-20 Baylor University Tubulin binding ligands and corresponding prodrug constructs
US7091240B2 (en) * 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
DE10017947A1 (de) 2000-04-11 2001-10-25 Merck Patent Gmbh Verfahren zur Herstellung benzo-annelierter Heterocyclen
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
FR2813308B1 (fr) 2000-08-23 2005-07-01 Sanofi Synthelabo Aminoalkoxybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation ainsi que les compositions les contenant
AU2002224890B2 (en) 2000-12-05 2007-03-22 F. Hoffmann-La Roche Ag Benzofuran and benzothiophene derivatives as selective COX-2 inhibitors
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
GB0106586D0 (en) 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
WO2003004485A1 (fr) 2001-07-05 2003-01-16 Takeda Chemical Industries, Ltd. Composes heterocycles a 5 chainons condenses avec un benzo, leur procede de preparation et leur utilisation
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
CA2523718A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
US20050245489A1 (en) * 2004-05-03 2005-11-03 Pinney Kevin G Chromene-containing compounds with anti-tubulin and vascular targeting activity
US7456214B2 (en) 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
AU2007211840B2 (en) 2006-02-03 2012-03-01 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006212726A1 (en) * 2005-02-14 2006-08-17 Bionomics Limited Novel tubulin polymerisation inhibitors

Also Published As

Publication number Publication date
US20120214770A1 (en) 2012-08-23
US20140171642A1 (en) 2014-06-19
HK1124329A1 (en) 2009-07-10
CA2640678C (en) 2015-03-31
US8198466B2 (en) 2012-06-12
US20130053351A1 (en) 2013-02-28
US9346842B2 (en) 2016-05-24
JP2009531281A (ja) 2009-09-03
AU2007211840A1 (en) 2007-08-09
EP1984333B1 (en) 2012-04-25
US8680135B2 (en) 2014-03-25
US8716335B2 (en) 2014-05-06
NZ570014A (en) 2011-04-29
US20100004208A1 (en) 2010-01-07
DK1984333T3 (da) 2012-07-23
JP5315060B2 (ja) 2013-10-16
EP2460793A1 (en) 2012-06-06
EP1984333A4 (en) 2010-05-19
CA2640678A1 (en) 2007-08-09
US10213409B2 (en) 2019-02-26
ATE555091T1 (de) 2012-05-15
ES2386299T3 (es) 2012-08-16
EP1984333A1 (en) 2008-10-29
US20170020840A1 (en) 2017-01-26
PT1984333E (pt) 2012-07-16
WO2007087684A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
AU2007211840B2 (en) Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
CA2597447C (en) Novel tubulin polymerisation inhibitors
AU2007332143B2 (en) Chemical compounds and processes
AU2013204313B2 (en) Combination Therapy
EP1077970A1 (en) 11-aryl-benzo(b)naphtho(2,3-d)furans and 11-aryl-benzo(b)naphtho(2,3-d)thiophenes useful in the treatment of insulin resistance and hyperglycemia
JPH10505089A (ja) 抗炎症剤として有用なジヒドロベンゾフラン及び関連化合物
AU2012203083A1 (en) Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
HK1171752A (en) Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
HK1124329B (en) Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired